Cargando…
Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13)
A high prevalence of antinuclear antibodies (ANA) in COVID-19 has been insinuated, but the nature of the target antigens is poorly understood. We studied ANA by indirect immunofluorescence in 229 individuals with COVID-19. The target antigens of high titer ANA (≥1:320) were determined by immunopreci...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893804/ https://www.ncbi.nlm.nih.gov/pubmed/36738952 http://dx.doi.org/10.1016/j.autrev.2023.103288 |
| _version_ | 1784881606344835072 |
|---|---|
| author | Bossuyt, Xavier Vulsteke, Jean-Baptiste Van Elslande, Jan Boon, Lise Wuyts, Greet Willebrords, Silke Frans, Glynis Geukens, Nick Carpentier, Sebastien Tejpar, Sabine Wildiers, Hans Blockmans, Daniel De Langhe, Ellen Vermeersch, Pieter Derua, Rita |
| author_facet | Bossuyt, Xavier Vulsteke, Jean-Baptiste Van Elslande, Jan Boon, Lise Wuyts, Greet Willebrords, Silke Frans, Glynis Geukens, Nick Carpentier, Sebastien Tejpar, Sabine Wildiers, Hans Blockmans, Daniel De Langhe, Ellen Vermeersch, Pieter Derua, Rita |
| author_sort | Bossuyt, Xavier |
| collection | PubMed |
| description | A high prevalence of antinuclear antibodies (ANA) in COVID-19 has been insinuated, but the nature of the target antigens is poorly understood. We studied ANA by indirect immunofluorescence in 229 individuals with COVID-19. The target antigens of high titer ANA (≥1:320) were determined by immunoprecipitation (IP) combined with liquid-chromatography-mass spectrometry (MS). High titer ANA (≥1:320) were found in 14 (6%) of the individuals with COVID-19. Of the 14 COVID-19 cases with high titer ANA, 6 had an underlying autoimmune disease and 5 a malignancy. IP-MS revealed known target antigens associated with autoimmune disease as well as novel autoantigens, including CDK9 (in systemic sclerosis) and RNF20, RCC1 and TRIP13 (in malignancy). The novel autoantigens were confirmed by IP-Western blotting. In conclusion, in depth analysis of the targets of high titer ANA revealed novel autoantigens in systemic sclerosis and in malignant disease. |
| format | Online Article Text |
| id | pubmed-9893804 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98938042023-02-02 Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) Bossuyt, Xavier Vulsteke, Jean-Baptiste Van Elslande, Jan Boon, Lise Wuyts, Greet Willebrords, Silke Frans, Glynis Geukens, Nick Carpentier, Sebastien Tejpar, Sabine Wildiers, Hans Blockmans, Daniel De Langhe, Ellen Vermeersch, Pieter Derua, Rita Autoimmun Rev Article A high prevalence of antinuclear antibodies (ANA) in COVID-19 has been insinuated, but the nature of the target antigens is poorly understood. We studied ANA by indirect immunofluorescence in 229 individuals with COVID-19. The target antigens of high titer ANA (≥1:320) were determined by immunoprecipitation (IP) combined with liquid-chromatography-mass spectrometry (MS). High titer ANA (≥1:320) were found in 14 (6%) of the individuals with COVID-19. Of the 14 COVID-19 cases with high titer ANA, 6 had an underlying autoimmune disease and 5 a malignancy. IP-MS revealed known target antigens associated with autoimmune disease as well as novel autoantigens, including CDK9 (in systemic sclerosis) and RNF20, RCC1 and TRIP13 (in malignancy). The novel autoantigens were confirmed by IP-Western blotting. In conclusion, in depth analysis of the targets of high titer ANA revealed novel autoantigens in systemic sclerosis and in malignant disease. Published by Elsevier B.V. 2023-04 2023-02-02 /pmc/articles/PMC9893804/ /pubmed/36738952 http://dx.doi.org/10.1016/j.autrev.2023.103288 Text en © 2023 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Bossuyt, Xavier Vulsteke, Jean-Baptiste Van Elslande, Jan Boon, Lise Wuyts, Greet Willebrords, Silke Frans, Glynis Geukens, Nick Carpentier, Sebastien Tejpar, Sabine Wildiers, Hans Blockmans, Daniel De Langhe, Ellen Vermeersch, Pieter Derua, Rita Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) |
| title | Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) |
| title_full | Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) |
| title_fullStr | Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) |
| title_full_unstemmed | Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) |
| title_short | Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) |
| title_sort | antinuclear antibodies in individuals with covid-19 reflect underlying disease: identification of new autoantibodies in systemic sclerosis (cdk9) and malignancy (rnf20, rcc1, trip13) |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893804/ https://www.ncbi.nlm.nih.gov/pubmed/36738952 http://dx.doi.org/10.1016/j.autrev.2023.103288 |
| work_keys_str_mv | AT bossuytxavier antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT vulstekejeanbaptiste antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT vanelslandejan antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT boonlise antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT wuytsgreet antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT willebrordssilke antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT fransglynis antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT geukensnick antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT carpentiersebastien antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT tejparsabine antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT wildiershans antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT blockmansdaniel antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT delangheellen antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT vermeerschpieter antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 AT deruarita antinuclearantibodiesinindividualswithcovid19reflectunderlyingdiseaseidentificationofnewautoantibodiesinsystemicsclerosiscdk9andmalignancyrnf20rcc1trip13 |